# Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed)

> **NCT00916630** · PHASE1 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 18 (actual)

## Conditions studied

- Central Nervous System Lymphoma

## Interventions

- **DRUG:** pemetrexed

## Key facts

- **NCT ID:** NCT00916630
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2015-09-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00916630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00916630, "Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed)". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT00916630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*